相关实验视频
Updated: Jul 3, 2025

08:03
In Vitro Model of Coronary Angiogenesis
Published on: March 10, 2020
7.7K
通过抑制VEGFR2信号通路来抑制血管新生,异素抑制血管新生
Yating Xu1,2, Di Xia1,3,4, Shan Deng5,6,7,8
1Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan, 430022, China.
Cardiovascular drugs and therapy
|February 16, 2024
概括
通过向VEGFR2信号通路,伊索伊佩拉托林有效地抑制血管生成. 这种天然化合物显示出作为治疗疾病的治疗剂的潜力,这些疾病是由异常的血管生长驱动的.
科学领域:
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 血管新生与瘤转移和糖尿病视网膜病变等病理过程有关.
- 向血管生成为各种疾病提供了一个有前途的治疗策略.
- 异 Imperatorin 是一种 furancoumarin,具有已知的抗炎和抗微生物特性.
研究的目的:
- 为了研究异素对血管内皮生长因子 (VEGF) 诱导的内皮血管生成的影响.
- 阐明伊索伊佩拉托林对血管生成作用的潜在机制.
主要方法:
- 在体外测试:扩散 (EDU结合),迁移 (穿孔,伤口愈合) 和管道形成.
- 西部斑点和免疫光学分析VEGFR2激活和下游信号.
- 在体内验证:matrigel插头测定和正管瘤模型.
主要成果:
- 在体外,伊索伊佩拉托林抑制了VEGF诱导的内皮细胞增殖,迁移和管形成.
- 该化合物在体内抑制了血管生成,使用matrigel插头和正管瘤模型.
- 通过抑制VEGFR2及其下游信号通路,Isoimperatorin的抗血管效应受到介导.
结论:
- 伊索伊佩拉托林显示出显著的抗血管性质.
- 该机制涉及抑制VEGFR2信号通路.
- 伊索伊佩拉托林是血管生成相关疾病的潜在治疗候选者.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
638
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
638

